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Abstract: Our expanding knowledge of immunotherapy for solid tumors has led to an explosion 
of clinical trials aimed at urothelial carcinoma. The primary strategy is centered on unleashing 
the immune system by releasing the inhibitory signals propagated by programmed cell death-1 
(PD-1) and its ligand programmed cell death ligand-1 (PD-L1). Many antibody constructs have 
been developed to block these interactions and are used in clinical trials. The Food and Drug 
Administration has already approved a number of checkpoint inhibitors such as anti-cytotoxic 
T-lymphocyte-associated protein 4 (CTLA4) monoclonal antibodies including ipilimumab; 
anti-PD-1 monoclonal antibodies including nivolumab and pembrolizumab; anti-PD-L1 
antibodies including atezolizumab, avelumab, and durvalumab. One of the latest inhibitors is 
durvalumab, which is a high-affinity human immunoglobulin G1 kappa monoclonal antibody 
and blocks the interaction of PD-L1 with PD-1 and CD80. Currently, there are a number of 
ongoing trials in advanced urothelial carcinoma both using durvalumab monotherapy and in 
combination with other targeted therapies. In addition, durvalumab is being investigated in the 
non-muscle-invasive urothelial carcinoma, which is centered around intravenous formulations. 
These exciting developments have added a significant number of therapies in a previously 
limited treatment landscape.
Keywords: durvalumab, checkpoint inhibitors, metastatic urothelial carcinoma
Introduction
Bladder cancer is the fourth most common cancer, with an estimated 76,960 new 
cases per year and an estimated 16,390 deaths.1 Systemic cisplatin-based combina-
tion chemotherapies were the standard of care for patients with metastatic urothelial 
bladder cancer (mUC) for the past 30 years up until recently when newer approvals 
occurred. First-line systemic regimens included methotrexate, vinblastine, doxorubicin, 
cisplatin (MVAC), and gemcitabine/cisplatin.2 Although a majority of patients with 
metastatic disease (40%–70%) experience an initial response to chemotherapy, all 
will ultimately progress with a median survival of 14 months and an overall 5-year 
survival rate of only 5%–20%. Poor response to chemotherapy is further compounded 
by many barriers to administer chemotherapy in this population where many patients 
already have coexisting comorbidities including renal insufficiency that may preclude 
them from receiving cisplatin therapy and instead being treated with carboplatin, 
which has lower response rates.3 However, the treatment arena in this first-line setting 
is changing with the introduction of immunooncology agents.2 Furthermore, different 
chemotherapy regimens such as taxanes and pemetrexed have been used as second- or 
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third-line treatments but again with decreased response rates 
signifying a need for more therapeutic options that are now 
finally becoming available.4
With the excitement over immunotherapy and its poten-
tial impact on cancer treatment, programmed cell death-1 
(PD-1) receptor and its ligands, programmed cell death-1 
ligand (PD-L1) and programmed cell death-2 ligand (PD-L2) 
inhibitors have emerged as important additions to the treat-
ment of mUC. Over the past year, there have been five Food 
and Drug Administration (FDA)-approved single agents that 
have changed the treatment landscape in urothelial cancer – 
in both the first- and second-line setting. PD-L1 and PD-L2 
are vital receptor ligands in T-cell immunomodulation and 
tolerance and have provided us with a critical target for 
cancer therapy. The PD-1 receptor is expressed on activated 
T cells, and PD-1–ligand interaction results in the inhibition 
of T-cell receptor (TCR)-mediated functions and the suppres-
sion of T-cell effector function. Furthermore, PD-1 activity 
is thought to act primarily in the tumor microenvironment, 
where it restrains T-cell-mediated tumor destruction.5 The 
upregulation of PD-L1 on tumor cells led to the activation 
of the PD-1 pathway as a mechanism of immune evasion.6 
Immunohistochemical studies have demonstrated that an 
increased PD-L1 expression is associated with increasing 
bladder tumor stage and grade.7
immunotherapies as a novel concept 
in cancer
Enlisting the power of the immune system to counter malig-
nancy is not unique to the 21st century. Spontaneous regres-
sion of tumors following erysipelas has been documented 
since the 17th century. Surgeon William Coley8 injected mix-
tures of attenuated bacteria into inoperable tumors leading 
to decreased tumor size in 190 of 312 cases in the 1890s. 
In the 1970s, intravesicar Bacillus Calmette–Guérin (BCG) 
vaccine, perhaps with some degree of serendipity, harnessed 
the antigenicity and immunogenicity of bladder cancer to 
achieve early-disease remission and prolong survival via an 
immunomediated antitumor response.9
Mechanism of action
Over the past 30 years, this immunomediated antitumor 
response has been drilled down to a T-cell-specific response, 
which dovetailed with the development of monoclonal 
antibodies,10 ushering in a new era of unbridled optimism 
in immunotherapy targeted to the immune checkpoint. The 
physiologic foundation of this response was well described 
by Chen and Mellman11 in 2013 as a cancer-immunity 
cycle initiated by the release of cancer cell antigens. In this 
model, cancer antigens are taken up by antigen-presenting 
cells (APCs), which prime and activate cytotoxic T cells 
that in turn travel to and infiltrate tumor. In the tumor 
microenvironment, primed TCRs recognize abnormal 
proteins expressed through major histocompatibility 
complex-I (MHC-I) of cancer cells, triggering granzyme 
and perforin release, leading to rupture of tumor cell 
membrane and destruction of the abnormal cell, starting 
the cycle over again.11 Obviously, as cancer is able to 
take hold in hosts with functioning immune systems, it is 
a fallible system, but it was not until the theory of cancer 
immunoediting that a model described how tumors have 
been able to evade immune destruction. Dunn et al12 sug-
gested a model in 2002 that described this process as one 
in which the immune system initially eliminates abnormal 
cancer cells, but it reaches a point of equilibrium in which 
tumor cell variants with increasing capacity to evade the 
immune system are selected, thus facilitating tumor escape 
from immunomediated destruction. Further research has 
described how immune-impenetrable phenotypes and robust 
tumor microenvironments13 as well as mutations disrupting 
MHC–T-cell interaction14 and interferon-gamma signaling15 
may contribute to tumor escape.
One of the proposed mechanisms of tumor escape is via 
the immune checkpoint, an umbrella term for the complex 
network of ligand–receptor co-signaling interactions on 
the T-cell surface.16 There are two main types of T-cell 
regulatory ligand–receptors: the immunoglobulin (Ig) 
or B7 superfamily and the tumor necrosis factor (TNF) 
family.17 The Ig family includes co-inhibitory receptors 
such as cytotoxic T-lymphocyte-associated protein 4 
(CTLA4) and PD-1, which interact with APC CD80 or 
CD86 or PD-L1, respectively.18 When these co-inhibitory 
receptors are engaged, T-cell activation is blocked via 
recruitment of Src homology 2 domain-containing protein 
tyrosine family phosphatases (SHPs), which reverse TCR 
activation-induced phosphorylation of signaling molecules, 
preventing the release of granyzmes and perforins even if 
a TCR has recognized abnormal protein on the MHC-I.19 
Co-stimulatory receptors, such as OX40, belong to the 
TNF family and, when activated, recruit TNF receptor 
(TNFR)-associated factors (TRAFs) that differentially 
activate mitogen-activated protein kinase (MAPK) signal-
ing cascades, promoting nuclear factor-κB that enhances 
cellular proliferation and function (Figure 1).17 Both 
mechanisms have been exploited, in vivo and in vitro, by 
monoclonal antibodies.
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Antibodies that have been designed to block negative 
co-stimulatory molecules or activate co-stimulatory mol-
ecules have been in development over the past decade. 
Current FDA-approved treatments include anti-CTLA4 
monoclonal antibodies including ipilimumab; anti-PD-1 
monoclonal antibodies including nivolumab and pembroli-
zumab; and anti-PD-L1 antibodies including atezolizumab, 
avelumab, and durvalumab. Ideally, by blocking receptors 
or ligands that dampen immune activity, these agents rein-
vigorate or expand T-cell anticancer response11 and may act 
by opsonizing tumor cells and triggering death or removal 
by antibody-dependent cellular cytotoxicity or phagocyto-
sis.16 Durvalumab is a human immunoglobulin G1 kappa 
monoclonal antibody that blocks the interaction of PD-L1 
with PD-1 and CD80 and works through this mechanism 
(Figure 2).
Patient selection
PD-1/L1 expression in both tumor and immune cells are 
often used as markers for response to inhibit T-cell function. 
Intuitively, patients who overexpress PD-1/L1 are more 
likely to show a favorable response when inhibited by the 
antibodies, which would release the breaks on the immune 
system. However, the expected response in these patients is 
underwhelming. Some theories suggest that there may be 
an unmeasured interplay between the ligand and the recep-
tor, or the tumor heterogeneity.20 Therefore, in practice, 
currently, patients are not selected based on the expression 
status. However, trials often sub-stratify patients based on the 
expression profile, which may inform further understanding 
of the tumor–immune milieu.
Metastatic urothelial carcinoma
Current therapies
The list of PD-1/L1 inhibitors continues to grow (Table 1). 
The efficacy of the agents in recent trials has led to the 
FDA approval for use in metastatic urothelial carcinoma. 
Atezolizumab, a PD-L1 inhibitor, was recently approved 
based on the Phase II IMvigor 210 (NCT02108652) trial.21 
The trial consisted of patients with locally advanced or 
metastatic urothelial carcinoma who were cisplatin ineligible 
(n=119) or who progressed after receiving platinum-based 
chemotherapy (n=310). The overall response rate (ORR) 
for the cohort in the second-line setting was 15% (95% CI, 
11%–20%; p=0.006) and conferred a median overall survival 
(OS) of 7.9 months and a 12-month OS of 36%. In patients 
who had tumor samples tested for PD expression, the ORR 
for IC2/3 was 27% (95% CI, 19%–37%; p,0.0001) and for 
IC1/2/3 was 18% (95% CI, 13%–24%; p=0.0004). The safety 
and efficacy of avelumab (PD-L1 inhibitor) were investigated 
in JAVELIN (NCT01772004), a Phase Ib trial in the second-
line setting (n=44).22 The ORR was 18.2%, five of whom 
had complete responses and three with partial responses. 
The median OS was 13.7 months. When stratifying by a 
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Figure 1 immune checkpoint paths and interactions.
Notes: Major inhibitory and stimulatory pathways through the TCR. CTLA4, PD-1 
and PD-L1, OX40 (tumor necrosis factor receptor superfamily, member 4), and 
OX40L, Pi3K-AKT, SHP2, and TRAF pathways.
Abbreviations: TCR, T-cell receptor; CTLA4, Cytotoxic T-lymphocyte-associated 
protein 4; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; 
OX40L, OX40 ligand; Pi3K-AKT, phosphoinositide 3-kinase-protein kinase B; SHP2, 
Src homology 2 domain-containing protein tyrosine phosphatase; TRAFs, tumor 
necrosis factor receptor-associated factors.
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Figure 2 Mechanism of durvalumab.
Notes: Durvalumab antibody blocks PD-1 and PD-L1 interaction, which prevents 
a SHP2-mediated co-inhibitory signal, allowing the neoepitope expressed by MHC-i 
to act as signal in stimulating an immune response, leading to the release of perforins 
and granzymes, theoretically leading to destruction of the tumor cell.
Abbreviations: PD-1, programmed cell death-1; PD-L1, programmed cell death 
ligand-1; SHP2, Src homology 2 domain-containing protein tyrosine phosphatase; 
MHC, major histo compatibility complex; TCR, T-cell receptor.
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PD-L1 expression cutoff of 5%, patients with positive and 
negative expressions had an ORR of 53.8% (7/13) and 4.2% 
(1/24), respectively. Pembrolizumab, a PD-1 inhibitor, was 
evaluated in KEYNOTE-045 (NCT02256436), which was 
a Phase III, open-label, 1:1 randomized trial of pembroli-
zumab versus investigator’s choice of docetaxel, paclitaxel, 
or vinflunine in patients who progressed on platinum-based 
chemotherapy.23 The median OS was 10.3 months (95% 
CI, 8.0–11.8) in the pembrolizumab group, compared with 
7.4 months (95% CI, 6.1–8.3) in the chemotherapy group 
(hazard ratio [HR], 0.73; 95% CI, 0.59–0.91; p=0.002), and 
this difference remains at the 2-year landmark. Furthermore, 
the median OS in patients who had a tumor PD-L1 expres-
sion score of $10% was 8.0 months (95% CI, 5.0–12.3) 
in the pembrolizumab group, compared with 5.2 months 
(95% CI, 4.0–7.4) in the chemotherapy group (HR, 0.57; 
95% CI, 0.37–0.88; p=0.005). Another PD-1 inhibitor, niv-
olumab, was evaluated in a Phase II trial (CheckMate 275; 
NCT02387996) looking at the primary endpoint of ORR in 
the second-line setting.24 There were 52 of 265 responders 
who achieved an ORR of 19.6% (95% CI, 15.0–24.9) with 
a median OS of 8.7 months. The ORR for patients with PD 
expression $5% was 23.8% (95% CI, 16.5–32.3) compared 
with only 16.1% (95% CI, 10.5–23.1) in patients with PD 
expression $1%.
Durvalumab
Durvalumab is an IgG1 monoclonal antibody that has high-
affinity binding to PD-L1 receptor. Currently, it is being 
evaluated for treatment in multiple malignancies in an ongo-
ing Phase I/II trial (NCT01693562). This study is evaluating 
the safety and efficacy of durvalumab in patients with urothe-
lial carcinoma among other histologies who progressed on 
chemotherapy and have never received any immunotherapy 
or refused other treatments. The main dose was 10 mg/kg 
every 2 weeks, for up to 12 months or up to progression, 
initiation of a different therapy, experience of intolerable side 
effects, or withdrawal. The primary endpoint is safety and 
secondary endpoint consisted of efficacy outcomes (ORR, 
disease control at 12 weeks, and PD expression status). 
The initial report was on 61 patients, 20 of whom initially 
enrolled regardless of PD-L1 expression status; however, 
subsequent patients were required to have .5% expression 
in the tumor cells for enrollment.25 Furthermore, given earlier 
data from small-cell lung cancer, they used a cutoff of $25% 
of tumor or immune cells expressing PD-L1 as positive as 
these patients were enriched for response. In this cohort, 
64% of patients had an adverse event (AE). The most com-
mon adverse events were fatigue, diarrhea, and decreased 
appetite. Grade 3 AE were reported in 4.9% of the patients 
with no grade 4 or 5 AE. The ORR was 31.0% (95% CI, 
17.6%–47.1%) with 46.4% in the PD-L1-positive subgroup 
(.25% expression) and 0% in the PD-L1-negative subgroup 
(,25% expression). The disease control rate at 12 months 
for the same subgroups was 57.1% and 28.6%, respectively. 
Responders in the PD-L1-positive subgroup had a median 
time to response of 6.3 weeks (95% CI, 5.6–12.1 weeks). 
Overall, this study demonstrated an effective and durable 
response rate with an acceptable safety profile.
In an update of the expansion cohort from the same 
trial (NCT01693562), 191 patients were enrolled with a 
significant proportion with relatively poor prognosis, 97% 
of whom had previous platinum-based therapy. In addition, 
95% had visceral metastases and 49% had liver metastases.26 
In the cohort, the ORR was 17.8% (95% CI, 12.7%–24.0%), 
which included seven patients with a complete response. 
The ORRs in PD-L1-positive patients was 27.6% (95% CI, 
19.0%–37.5%) compared with 5.1% (95% CI, 1.4%–12.5%) 
in PD-L1-negative patients. The response rate in other sub-
groups was also significant. In patients with lymph node 
metastases, the ORR was 50.0% (95% CI, 23.0%–77.0%). 
In patients with visceral metastases or liver metastases, the 
ORR was 15.3% (95% CI, 10.3%–21.4%) and 7.3% (95% 
CI, 2.7%–15.2%), respectively. With limited follow-up, the 
progression-free survival (PFS) was 2.1 months (95% CI, 
1.4–2.8) in the PD-L1-positive group and 1.4 months in 
the PD-L1-negative group (95% CI, 1.3–1.5). In addition, 
the data for OS were immature, but the authors report a 
median OS of 18.2 months in the treated group. The safety 
profile report consisted of common AEs, which were fatigue 
Table 1 Approved drugs for locally advanced or metastatic urothelial carcinoma
Drug Target Trial Indication Phase ORR (%) Median OS 
(months)
PFS 
(months)
Atezolizumab PD-L1 NCT02108652 Cis-ineligible or progression on platinum ii 15 7.9 2.1
Avelumab PD-L1 NCT01772004 Progression on platinum ib 18.2 13.7 11.6 (w)
Pembrolizumab PD-1 NCT02256436 Progression on platinum iii 21.1 10.3 2.1
Nivolumab PD-1 NCT02387996 Progression on platinum ii 19.6 8.7 NR
Durvalumab PD-L1 NCT01693562 Progression on platinum i/ii 17.8 18.2 2.1
Abbreviations: ORR, overall response rate; OS, overall survival; PD-L1, programmed cell death ligand-1; PFS, progression-free survival; NR, non reported; w, weeks.
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(19.4%), decreased appetite (9.4%), diarrhea (8.4%), and rash 
(7.3%). Overall, grade 3 or 4 treatment-related AEs occurred 
in 6.8% of the trial cohort.
Currently, the Phase III trial DANUBE (NCT02516241) 
is evaluating durvalumab in the first-line setting in patients 
with locally advanced or metastatic urothelial carcinoma. 
In this trial, patients are randomized to durvalumab mono-
therapy, durvalumab combination therapy with tremelimumab 
(anti-CTLA-4 antibody), or standard of care chemotherapy 
(either cisplatin–gemcitabine or carboplatin–gemcitabine). 
Patients are further stratified by eligibility to receive chemo-
therapy based on the PD-L1 expression and the presence or 
absence of visceral metastases. The primary endpoints are 
PFS and OS. To date, the results are pending.
Despite the success of monotherapy, there are still 
patients who progress or do not respond to initial treatment, 
which sparked an interest in combination therapy. Ongo-
ing trials include BISCAY (NCT02546661), which is a 
Phase Ib trial recruiting patients with metastatic UC who 
are randomized to durvalumab in combination with multiple 
agents (durvalumab monotherapy, durvalumab + AZD4547 
[fibroblast growth factor receptor tyrosine kinase family 
inhibitor], durvalumab + olaparib [poly(ADP-ribose) poly-
merase inhibitor], durvalumab + AZD1775 [Wee1 kinase 
inhibitor], and durvalumab + vistusertib [mammalian target 
of rapamycin]) with primary safety endpoint. This trial will 
be offered to patients who are immunotherapy naive. In the 
Phase II BASKET study (NCT02527434), patients with 
metastatic urothelial cancer with or without prior treatment 
with PD1 or PD-L1 inhibitors were recruited to receive the 
combination of tremelimumab with durvalumab. The primary 
endpoint is objective response rate, and the results of this 
study are still pending. Finally, a combination of durvalumab 
and tremelimumab with or without a toll-like receptor 3 
agonist (PolyICLC) is being evaluated in a Phase I/II trial 
(NCT02643303) with the primary endpoint being safety and 
tolerability as well as ORR, PFS, and OS.
Non-muscle-invasive bladder cancer 
(NMIBC)
Current therapies
Treatments for NMIBC represent the earliest forms of immu-
notherapy for bladder cancer. The introduction of BCG to 
the armamentarium by the urologist was revolutionary as 
it provided a local treatment with manageable side effects 
with durable efficacy and is currently the preferred adju-
vant treatment for high-risk NMIBC.27 Although the exact 
underlying mechanisms of the efficacy of intravesical BCG 
are incompletely elucidated, it is generally accepted that 
immune response to BCG plays a part28 in conjunction with 
both urothelial cells and bladder cancer cells.29 However, 
there is a high failure rate associated with BCG treatment 
that includes recurrence and more worrisome, progression. 
Furthermore, production shortages for BCG have placed 
constraints on treatment of NMIBC. As such, there is an 
increased pressure for other treatment strategies with similar 
efficacy. Current treatments center upon chemotherapeutic 
agents delivered intravesically in the second-line setting such 
as mitomycin C, thiotepa, gemcitabine, docetaxel, valrubicin, 
and epirubicin with different combinations thereof with or 
without immune modulators (eg, interleukin-15).
There has been great interest in potentiating the immune 
system as it has clearly worked using BCG. The excitement 
with the efficacy of checkpoint inhibitors in the advanced 
UC setting has spilled over to the NMIBC setting. This is 
reasonable as PD-L1 expression in tumor cells has been 
associated with prior BCG treatment, perhaps pointing to 
a potential resistance mechanism.30 Currently, there are a 
number of trials incorporating checkpoint inhibitors in the 
second-line setting. For example, an ongoing Phase II trial 
(NCT02844816) is evaluating the complete response rate 
in BCG-unresponsive patients using IV atezolizumab every 
21 days for up to 17 courses (51 weeks) in the absence 
of disease progression or unacceptable toxicity. Another 
Phase II trial (NCT02625961) is evaluating pembrolizumab 
(IV 200 mg Q3 weeks) in BCG-unresponsive patients. 
Treatment duration is 24 months or until disease recurrence 
or progression, unacceptable toxicity, withdrawal, or inves-
tigator decision. The patients are further stratified by the 
presence or absence of CIS based on tissue pathology at 
screening. Follow-up plan is cystoscopy and urine cytology 
every 12 weeks for the first 2 years, every 24 weeks for the 
following 2 years, and every 52 weeks thereafter. Co-primary 
endpoints are complete response rate and disease-free sur-
vival. Other strategies are to combine checkpoint inhibitors 
with BCG. A Phase Ib/II trial (NCT02792192) is assess-
ing the safety and tolerability of IV atezolizumab infusion 
alone and in combination with intravesical BCG in high-risk 
NMIBC patients. Other strategies include using intravesical 
checkpoint inhibitors, as a current Phase I dose escalation 
trial (NCT02808143) aims to assess the safety of combina-
tion intravesical BCG and pembrolizumab in patients with 
refractory NMIBC.
Durvalumab in NMiBC
Given the evidence that durvalumab is effective in advanced 
setting, currently, it is being studied in patients with non-
muscle-invasive disease. A Phase II trial (NCT02901548) 
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is under way to assess the combination of IV durvalumab 
and BCG in patients with BCG-refractory disease. The main 
inclusion criteria are high-grade carcinoma in situ (CIS) at 
6 months after BCG treatment, progression at 3 months after 
induction BCG, recurrence of high-grade CIS, or persistent 
CIS noted in the bladder biopsies within 3 months of complet-
ing at least two induction treatments with BCG. Patients will 
be assigned to a single arm of IV durvalumab 1,500 mg/kg Q4 
weeks for a total of 12 months. Posttreatment assessment will 
include cystoscopy with biopsy and transurethral resection of 
the bladder tumor (TURBT) at baseline, 3, 6, 9, 12, 18, and 
24 months after the first treatment. Mapping biopsies will 
be conducted at 6 and 24 months. The primary outcome is 
complete response rate at 6 months, whereas the secondary 
endpoint is complete response rate at 24 months.
Conclusion
In the past decade, the use of monoclonal antibodies to 
unshackle T-cells from their checkpoint inhibition has 
revolutionized immunotherapy, but the treatment remains 
fettered by unreliable responses, late relapses, unpredictable 
autoimmune phenomena, and complex microenvironment 
interactions limiting our ability to select likely responders. 
Both innate and adaptive checkpoint inhibitor resistances 
have been described,13 and the field is rapidly accumulating 
whole-exome sequencing data correlated with clinical 
information to tease apart the nuances of the complicated 
interaction between the immune system and the cancer 
growth. Human leukocyte antigen heterogeneity, mutational 
load, TCR clonality, and T-cell tumor penetration are all 
active areas of interest.
While we are awaiting the results of further translational 
research, clinical data continue to amass. Investigators of 
checkpoint inhibitor clinical trials have strategized to manip-
ulate subpar ORR by bringing the agents front line21,31 or as 
neoadjuvant32,33 treatment, more carefully selecting patients 
through biomarkers34–36 and combining immunotherapies37–40 
or combining approaches. These strategies have been met 
with variable success. More recently, attention has been 
directed toward combining checkpoint inhibitors with 
other treatments with nonoverlapping toxicities, such as 
chemotherapy36,41,42 or other inhibitors of tumor-mediated 
immune suppression outside the immune checkpoint 
pathways.43 While somewhat controversial, this approach 
stands on the foundation of work by Galluzzi et al44,45 who 
revealed that certain types of chemotherapy and radiation 
may heighten antigenicity and adjuvanticity and improve 
response to checkpoint inhibition.
As our treatment armamentarium for urothelial carci-
noma continues to expand, checkpoint inhibitors appear at 
the center of the current treatment paradigm. Many trials are 
currently ongoing to refine our treatment strategies while 
exploring more novel ways to approach treatment in hopes 
of providing hope for an otherwise lethal disease.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J 
Clin. 2016;66(1):7–30.
 2. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of 
an EORTC phase III trial of high-dose intensity M-VAC chemotherapy 
and G-CSF versus classic M-VAC in advanced urothelial tract tumours. 
Eur J Cancer. 2006;42(1):50–54.
 3. Bellmunt J, Petrylak DP. New therapeutic challenges in advanced 
bladder cancer. Semin Oncol. 2012;39(5):598–607.
 4. Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of pemetr-
exed for second-line treatment of transitional cell cancer of the urothe-
lium. J Clin Oncol. 2006;24(21):3451–3457.
 5. Donin NM, Lenis AT, Holden S, et al. Immunotherapy in the treatment 
of urothelial carcinoma. J Urol. 2017;197(1):14–22.
 6. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 
promotes T-cell apoptosis: a potential mechanism of immune evasion. 
Nat Med. 2002;8(8):793–800.
 7. Huang Y, Zhang SD, McCrudden C, Chan KW, Lin Y, Kwok HF. 
The prognostic significance of PD-L1 in bladder cancer. Oncol Rep. 
2015;33(6):3075–3084.
 8. Nauts HC, Swift WE, Coley BL. The treatment of malignant tumors 
by bacterial toxins as developed by the late William B Coley, M.D., 
reviewed in the light of modern research. Cancer Res. 1946;6: 
205–216.
 9. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-
Guerin in the treatment of superficial bladder tumors. J Urol. 1976; 
116(2):180–183.
 10. Kohler G, Milstein C. Continuous cultures of fused cells secreting 
antibody of predefined specificity. Nature. 1975;256(5517):495–497.
 11. Chen DS, Mellman I. Oncology meets immunology: the cancer-
immunity cycle. Immunity. 2013;39(1):1–10.
 12. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immu-
noediting: from immunosurveillance to tumor escape. Nat Immunol. 
2002;3(11):991–998.
 13. Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic fea-
tures of response to anti-PD-1 therapy in metastatic melanoma. Cell. 
2016;165(1):35–44.
 14. del Campo AB, Kyte JA, Carretero J, et al. Immune escape of cancer 
cells with beta2-microglobulin loss over the course of metastatic mela-
noma. Int J Cancer. 2014;134(1):102–113.
 15. Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon receptor sig-
naling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 
2017;19(6):1189–1201.
 16. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of 
age. Nature. 2011;480(7378):480–489.
 17. Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling 
molecules for immune modulation. Nat Rev Drug Discov. 2013;12(2): 
130–146.
 18. Pardoll DM. The blockade of immune checkpoints in cancer immuno-
therapy. Nat Rev Cancer. 2012;12(4):252–264.
 19. Ribas A. Releasing the brakes on cancer immunotherapy. N Engl J 
Med. 2015;373(16):1490–1492.
Drug Design, Development and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal
Drug Design, Development and Therapy is an international, peer-
reviewed open-access journal that spans the spectrum of drug design 
and development through to clinical applications. Clinical outcomes, 
patient safety, and programs for the development and effective, safe, 
and sustained use of medicines are the features of the journal, which 
has also been accepted for indexing on PubMed Central. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Drug Design, Development and Therapy 2018:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
215
Review of durvalumab
 20. Drake CG, Bivalacqua TJ, Hahn NM. Programmed cell death ligand-1 
blockade in urothelial bladder cancer: to select or not to select. J Clin 
Oncol. 2016;34(26):3115–3116.
 21. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in 
patients with locally advanced and metastatic urothelial carcinoma who 
have progressed following treatment with platinum-based chemother-
apy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031): 
1909–1920.
 22. Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti-
programmed death-ligand 1 antibody, In patients with refractory 
metastatic urothelial carcinoma: results from a multicenter, phase Ib 
study. J Clin Oncol. 2017;35(19):2117–2124.
 23. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-
line therapy for advanced urothelial carcinoma. N Engl J Med. 2017; 
376(11):1015–1026.
 24. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic 
urothelial carcinoma after platinum therapy (CheckMate 275): a multi-
centre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–322.
 25. Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of dur-
valumab (MEDI4736), an anti-programmed cell death ligand-1 immune 
checkpoint inhibitor, in patients with advanced urothelial bladder 
cancer. J Clin Oncol. 2016;34(26):3119–3125.
 26. Powles T, O’Donnell PH, Massard C, et al. Efficacy and safety of 
durvalumab in locally advanced or metastatic urothelial carcinoma: 
updated results from a phase 1/2 open-label study. JAMA Oncol. 2017; 
3(9):e172411.
 27. Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-
Guerin reduces the risk of progression in patients with superficial 
bladder cancer: a meta-analysis of the published results of randomized 
clinical trials. J Urol. 2002;168(5):1964–1970.
 28. Patard JJ, Saint F, Velotti F, Abbou CC, Chopin DK. Immune response 
following intravesical bacillus Calmette-Guerin instillations in super-
ficial bladder cancer: a review. Urol Res. 1998;26(3):155–159.
 29. Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of 
action of BCG therapy for bladder cancer – a current perspective. Nat 
Rev Urol. 2014;11(3):153–162.
 30. Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by 
urothelial carcinoma of the bladder and BCG-induced granulomata: 
associations with localized stage progression. Cancer. 2007;109(8): 
1499–1505.
 31. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line 
treatment in cisplatin-ineligible patients with locally advanced and 
metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 
trial. Lancet. 2017;389(10064):67–76.
 32. Chaft JE, Forde PM, Smith KN, et al. Neoadjuvant nivolumab in 
early-stage, resectable non-small cell lung cancers [abstract]. American 
Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL; 
2017. Abstract number 8505.
 33. Uppaluri R, Zolkind P, Lin T, et al. Neoadjuvant pembrolizumab in 
surgically resectable, locally advanced HPV negative head and neck 
squamous cell carcinoma (HNSCC) [abstract]. American Society of 
Clinical Oncology Annual Meeting (ASCO) Annual Meeting. Chicago, 
IL; 2017. Abstract number 6012.
 34. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of 
non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028.
 35. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab 
versus chemotherapy for PD-L1-positive non-small-cell lung cancer. 
N Engl J Med. 2016;375(19):1823–1833.
 36. Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in 
stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 
2017;376(25):2415–2426.
 37. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab 
versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 
372(21):2006–2017.
 38. Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and 
ipilimumab versus ipilimumab alone in patients with advanced mela-
noma: 2-year overall survival outcomes in a multicentre, randomised, 
controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558–1568.
 39. Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipili-
mumab as first-line treatment for advanced non-small-cell lung cancer 
(CheckMate 012): results of an open-label, phase 1, multicohort study. 
Lancet Oncol. 2017;18(1):31–41.
 40. Antonia SJ, Gettinger SN, Goldman J, et al. ORAL01.03: CheckMate 
012: safety and efficacy of first-line nivolumab and ipilimumab in 
advanced NSCLC: topic: medical oncology. J Thorac Oncol. 2016; 
11(11S):S250–S251.
 41. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed 
with or without pembrolizumab for advanced, non-squamous non-
small-cell lung cancer: a randomised, phase 2 cohort of the open-label 
KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–1508.
 42. Paz-Ares L, Brahmer J, Hellman MD, et al. CheckMate 227: a random-
ized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, 
or nivolumab plus chemotherapy versus chemotherapy in advanced non-
small cell lung carcinoma [abstract]. European Lung Cancer Conference 
(ELCC). Geneva, Switzerland; 2017. Abstract number 144TiP.
 43. Hamid O, Bauer TM, Spira AI, et al. Safety of epacadostat 100 mg bid 
plus pembrolizumab 200 mg Q3W in advanced solid tumors: phase 2 
data from ECHO-202/KEYNOTE-037 [abstract]. American Society of 
Clinical Oncology (ASCO) Annual Meeting. Chicago, IL; 2017. Abstract 
number 3012.
 44. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological 
effects of conventional chemotherapy and targeted anticancer agents. 
Cancer Cell. 2015;28(6):690–714.
 45. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic 
cell death in cancer and infectious disease. Nat Rev Immunol. 2017; 
17(2):97–111.
